Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Personalis Yönetim

Yönetim kriter kontrolleri 1/4

Personalis' CEO'su Chris Hall, Dec2022 tarihinde atandı, in görev süresi 1.83 yıldır. in toplam yıllık tazminatı $ 1.73M olup, şirket hissesi ve opsiyonları dahil olmak üzere 30.9% maaş ve 69.1% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.063% ine doğrudan sahiptir ve bu hisseler € 173.96K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.2 yıl ve 2.4 yıldır.

Anahtar bilgiler

Chris Hall

İcra Kurulu Başkanı

US$1.7m

Toplam tazminat

CEO maaş yüzdesi	30.9%
CEO görev süresi	1.8yrs
CEO sahipliği	0.06%
Yönetim ortalama görev süresi	3.2yrs
Yönetim Kurulu ortalama görev süresi	2.4yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Chris Hall'un ücretlendirmesi Personalis'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$81m
Mar 31 2024	n/a	n/a	-US$93m
Dec 31 2023	US$2m	US$534k	-US$108m
Sep 30 2023	n/a	n/a	-US$113m
Jun 30 2023	n/a	n/a	-US$110m
Mar 31 2023	n/a	n/a	-US$114m
Dec 31 2022	US$2m	US$83k	-US$113m

Tazminat ve Piyasa: Chris 'nin toplam tazminatı ($USD 1.73M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.29M ).

Tazminat ve Kazançlar: Chris şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Chris Hall (55 yo)

1.8yrs

Görev süresi

US$1,726,790

Tazminat

Mr. Christopher M. Hall, also known as Chris, served as Senior Vice President and Head of Diagnostics Business at Personalis, Inc. since October 2022 until December 31, 2022 and serves as its President sin...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Christopher Hall	President	1.8yrs	US$1.73m	0.063% € 160.5k
Aaron Tachibana	CFO & COO	5.6yrs	US$1.67m	0.27% € 692.3k
Stephen Moore	Senior VP & Chief Legal Officer	4.5yrs	US$674.28k	0.12% € 309.7k
Richard Chen	Executive VP of R&D and Chief Medical Officer	3.3yrs	US$1.28m	0.19% € 476.9k
Russ Altman	Co-Founder and Member of Clinical & Scientific Advisory Board	no data	Veri yok	Veri yok
Euan Ashley	Co-Founder and Member of Clinical & Scientific Advisory Board	no data	Veri yok	Veri yok
Michael Snyder	Co-Founder and Member of Clinical & Scientific Advisory Board	no data	Veri yok	Veri yok
Michael Fitzpatrick	Vice President of Worldwide Sales	11.5yrs	Veri yok	Veri yok
Christian Haudenschild	Senior Vice President of Genomic Laboratory Operations	3.1yrs	Veri yok	Veri yok
Stephane Mouradian	Senior Vice President of Business Development	1.8yrs	Veri yok	Veri yok
Deepshikha Bhandari	Senior Vice President of Regulatory	less than a year	Veri yok	Veri yok

3.2yrs

Ortalama Görev Süresi

53yo

Ortalama Yaş

Deneyimli Yönetim: 04X 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.2 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Christopher Hall	President	1.6yrs	US$1.73m	0.063% € 160.5k
Russ Altman	Co-Founder and Member of Clinical & Scientific Advisory Board	no data	Veri yok	Veri yok
Euan Ashley	Co-Founder and Member of Clinical & Scientific Advisory Board	no data	Veri yok	Veri yok
Michael Snyder	Co-Founder and Member of Clinical & Scientific Advisory Board	no data	Veri yok	Veri yok
Kenneth Widder	Independent Director	1.3yrs	US$154.00k	Veri yok
Karin Eastham	Independent Chair of the Board	5.1yrs	US$173.05k	0.024% € 60.5k
Arthur Bowman	Independent Director	5.4yrs	US$121.38k	0.024% € 60.5k
Woodrow Myers	Independent Director	3.6yrs	US$108.88k	0.046% € 117.1k
John West	Advisor to the Board	1.8yrs	US$5.62m	Veri yok
Lonnie Shoff	Independent Director	2.2yrs	US$103.88k	0.018% € 46.2k
Olivia Bloom	Independent Director	2.6yrs	US$116.38k	0.031% € 78.9k

2.4yrs

Ortalama Görev Süresi

67yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 04X 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2.4 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Personalis Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Personalis, Inc., Annual General Meeting, May 17, 2024

Personalis, Inc. Appoints Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance

Personalis, Inc. Announces Board Changes

High number of new directors

Personalis, Inc. Announces Retirement of John West from the Board of Directors

Personalis, Inc. Appoints Christopher Hall as SVP and Head, Diagnostics Business

Recent updates

Personalis, Inc. announced that it expects to receive $17.745 million in funding from Tempus AI, Inc

Second quarter 2024 earnings released: US$0.24 loss per share (vs US$0.50 loss in 2Q 2023)

Personalis, Inc. Revises Earnings Guidance for the Year 2024

Personalis, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Personalis, Inc. Revises Earnings Guidance for the Full Year of 2024

First quarter 2024 earnings released: US$0.26 loss per share (vs US$0.61 loss in 1Q 2023)

Personalis, Inc. to Report Q1, 2024 Results on May 08, 2024

Personalis, Inc., Annual General Meeting, May 17, 2024

Personalis, Inc. Announces Publication Validating Next Personal Test for Ultra-Sensitive MRD Detection and Cancer Treatment Response Monitoring

Full year 2023 earnings released: US$2.25 loss per share (vs US$2.48 loss in FY 2022)

Personalis, Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2024

Personalis, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Personalis Announces Medicare Coverage for Next Dx(R) Comprehensive Genomic Tumor Profiling Assay

Personalis, Inc. Provides Unaudited Preliminary Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2023

Personalis, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Third quarter 2023 earnings released: US$0.60 loss per share (vs US$0.58 loss in 3Q 2022)

Personalis, Inc. Provides Earnings Guidance for the Fourth Quarter of 2023

Personalis, Inc. Launches NeXT Personal DX for Early Access Clinical Use in Residual Disease and Recurrence Detection in Cancer

Personalis, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Personalis, Inc. Announces the Presentation of Initial Findings from Its Work with the Tracerx Lung Cancer Study

Personalis, Inc. Appoints Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance

New minor risk - Shareholder dilution

Personalis, Inc. Provides Earnings Guidance for the Third Quarter and Full Year of 2023

Second quarter 2023 earnings released: US$0.50 loss per share (vs US$0.60 loss in 2Q 2022)

Personalis, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Personalis, Inc. Announces Board Changes

High number of new directors

First quarter 2023 earnings released: US$0.61 loss per share (vs US$0.63 loss in 1Q 2022)

Personalis, Inc. Provides Earnings Guidance for the Full Year 2023

Full year 2022 earnings released: US$2.48 loss per share (vs US$1.49 loss in FY 2021)

Personalis, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Personalis, Inc. Provides Revenue Guidance for the Fourth Quarter Ended December 31, 2022

Personalis, Inc. Announces Retirement of John West from the Board of Directors

Third quarter 2022 earnings released: US$0.58 loss per share (vs US$0.40 loss in 3Q 2021)

Personalis, Inc. Provides Earnings Guidance for the Full Year of 2022

Personalis, Inc. Appoints Christopher Hall as SVP and Head, Diagnostics Business

Personalis, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Second quarter 2022 earnings released: US$0.60 loss per share (vs US$0.34 loss in 2Q 2021)

Personalis, Inc. Provides Earnings Guidance for the Year 2022

Personalis, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Personalis, Inc.(NasdaqGM:PSNL) dropped from Russell 2000 Growth Index

First quarter 2022 earnings released: US$0.63 loss per share (vs US$0.29 loss in 1Q 2021)

Personalis, Inc. Provides Earnings Guidance for the Full Year of 2022

High number of new directors

Personalis, Inc. to Report Q1, 2022 Results on May 04, 2022

Personalis Announces Issuance of Additional US Patent Related to the Next Personal Platform

Personalis, Inc., Annual General Meeting, May 17, 2022

High number of new directors

No longer forecast to breakeven

Personalis, Inc. Provides Earnings Guidance for the Full Year 2022

Forecast to breakeven in 2024

Personalis, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Personalis, Inc. Provides Unaudited Preliminary Revenue Guidance for the Fourth Quarter and Full Year of 2021

Personalis Launches NeXT Personal™, A Tumor-Informed Liquid Biopsy Assay for MRD and Recurrence Detection With Part-Per-Million Sensitivity

Third quarter 2021 earnings released: US$0.40 loss per share (vs US$0.27 loss in 3Q 2020)

Senior VP & CFO recently sold €57k worth of stock

Chief Financial Officer recently sold €71k worth of stock

Second quarter 2021 earnings released: US$0.34 loss per share (vs US$0.29 loss in 2Q 2020)

Chief Financial Officer recently sold €51k worth of stock

Independent Director has left the company

Personalis, Inc. Provides Financial Guidance for the Second Quarter and Full Year of 2021

First quarter 2021 earnings released: US$0.29 loss per share (vs US$0.29 loss in 1Q 2020)

Chief Financial Officer recently sold €55k worth of stock

Personalis, Inc. Announces Board Changes

Chief Financial Officer recently sold €82k worth of stock

Independent Director has left the company

New 90-day low: €22.00

Revenue beats expectations

Full year 2020 earnings released: US$1.20 loss per share (vs US$1.39 loss in FY 2019)